Cardiff Oncology CEO Adds to Stake with Recent Share Purchase

On June 18, 2026, Mani Mohindru, the CEO of Cardiff Oncology, Inc. (NasdaqCM: CRDF), purchased 24,703 shares of the company at an average price of $1.21 per share. This transaction, not planned under Rule 10b5-1, was valued at approximately $29,890.63.

Insider Buying and Selling at Cardiff Oncology, Inc.

In addition to Mani Mohindru's purchase, several other insiders made transactions around the same time. On June 18, Gary Pace bought 30,000 shares at $1.22 each. Earlier, on June 11, insiders including Gary Pace, Renee Tannenbaum, Rodney Markin, and James Armitage each acquired 40,565 shares at no stated purchase price.

Other Institutional Activity in Cardiff Oncology

Several institutional investors have been adjusting their positions in Cardiff Oncology. BlackRock, Inc. reduced its holding by 62,227 shares, bringing its total to 3,981,387 shares valued at about $6,449,847, a 1.5% decrease. Vanguard Capital Management LLC opened a new position with 2,855,966 shares worth approximately $4,626,665. Meanwhile, Geode Capital Management, LLC increased its stake by 76,648 shares, ending with 1,599,663 shares valued at $2,592,106, marking a 5% increase.

Cardiff Oncology, Inc. Stock Up 38.3%

Shares of Cardiff Oncology traded near $1.30 on Tuesday. The company has a market cap of approximately $88.88 million and a beta of 1.384, indicating moderate volatility. The stock's 52-week low is $1.16, and its high is $4.56. Cardiff Oncology's 50-day moving average is $1.63, while its 200-day moving average is $2.02. The company maintains a current ratio of 3.27 and a quick ratio of 3.20, with a debt-to-equity ratio of 1.86.

Analysts Set New Price Targets

On June 3, 2026, Craig-Hallum downgraded Cardiff Oncology to a hold rating with a price target of $2. Piper Sandler, however, maintained its buy rating with a target of $6 as of February 25, 2026. The consensus among analysts is a buy rating, with an average target price of $5.36 based on seven opinions.

About Cardiff Oncology

Cardiff Oncology, Inc. is a biotechnology company based in San Diego, California. It focuses on developing innovative cancer therapies. The company's leading drug candidate, Onvansertib, targets RAS-mutated metastatic colorectal cancer. Cardiff Oncology is also engaged in trials for other cancer types, including pancreatic ductal adenocarcinoma and small cell lung cancer. Founded in 1999, the company employs around 30 people and is led by CEO Dr. Mani Mohindru.

Bottom Line

Mani Mohindru's recent share purchase highlights insider confidence in Cardiff Oncology. Investors often track such transactions as a sign of potential growth or stability. However, it's important to remember that insider trades are just one factor to consider, and this information reflects past activity, not current conditions.